Sign in to view content

Twelve Month Safety and Efficacy Outcomes from a Phase 2 Study of APL-2 in Patients with Geographic Atrophy

David S. Boyer, MD

Video
Published 2017

Related

ARMD With Geographic Atrophy, Peripheral Degeneration
James B. Soque, CRA, OCT-C, COA, FOPS
Pamela Ann Weber, MD
Retina Image Bank: Images of the Week
2013
Patients Ultra-Responsive to Ranibizumab (RBZ): Rates of Great Than or Equal to 4-Step Improvement in Diabetic Retinopathy Severity in DRCR.net Protocol S
Allen Chiang, MD, FASRS
Annual Meeting Talks
2019
Should We Ever Consider Stopping Treatment for Neovascular AMD?
Rahul N. Khurana, MD, FASRS
Updates from the Field
2020

Category: AMD-Neovascular

See more